BDBM171350 1-(2-((1R,3S,5R)-3-((6-Bromopyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1H-indazole-3-carboxamide (7)::US9085555, 727

SMILES c1ccc2c(c1)c(nn2CC(=O)N3[C@@H]4C[C@@H]4C[C@H]3C(=O)Nc5cccc(n5)Br)C(=O)N

InChI Key InChIKey=CWZUTHDJLNZLCM-UHFFFAOYSA-N

Data  11 IC50

PDB links: 1 PDB ID matches this monomer.

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 11 hits for monomerid = 171350   

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM171350(1-(2-((1R,3S,5R)-3-((6-Bromopyridin-2-yl)carbamoyl...)
Affinity DataIC50: 9nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2016
Entry Details
Go to US Patent
PDB3D3D Structure (crystal)
TargetComplement factor D [24-253](Human)
Novartis Pharma

LigandPNGBDBM171350(1-(2-((1R,3S,5R)-3-((6-Bromopyridin-2-yl)carbamoyl...)
Affinity DataIC50: 6nMpH: 7.5 T: 2°CAssay Description:Briefly, recombinant human or murine FD catalytic domain (10 nM concentration) were incubated with compound at various concentrations for 1 h at room...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2016
Entry Details Article
PubMedPDB3D3D Structure (crystal)
TargetComplement factor D [24-253](Human)
Novartis Pharma

LigandPNGBDBM171350(1-(2-((1R,3S,5R)-3-((6-Bromopyridin-2-yl)carbamoyl...)
Affinity DataIC50: 20nMpH: 7.4 T: 2°CAssay Description:Recombinant human FD (10 nM concentration) was incubated with compound at various concentrations for 1 h at room temperature in 0.1 M PBS (pH 7.4) co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2016
Entry Details Article
PubMedPDB3D3D Structure (crystal)
TargetKallikrein-7 [37-253,Y180R](Human)
Novartis Pharma

LigandPNGBDBM171350(1-(2-((1R,3S,5R)-3-((6-Bromopyridin-2-yl)carbamoyl...)
Affinity DataIC50: 1.00E+5nMpH: 5.6 T: 2°CAssay Description:Recombinant human KLK7 (5 nM concentration) was pre-incubated with inhibitor at various concentrations for 1 h at room temperature in 50 mM sodium ci...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2016
Entry Details Article
PubMed
TargetCytochrome P450 3A4(Human)
Novartis Pharma

Curated by ChEMBL
LigandPNGBDBM171350(1-(2-((1R,3S,5R)-3-((6-Bromopyridin-2-yl)carbamoyl...)
Affinity DataIC50: 1.70E+4nMAssay Description:Inhibition of CYP3A4 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/30/2019
Entry Details Article
PubMed
TargetCytochrome P450 2D6(Human)
Novartis Pharma

Curated by ChEMBL
LigandPNGBDBM171350(1-(2-((1R,3S,5R)-3-((6-Bromopyridin-2-yl)carbamoyl...)
Affinity DataIC50: 2.00E+4nMAssay Description:Inhibition of CYP2D6 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/30/2019
Entry Details Article
PubMed
TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM171350(1-(2-((1R,3S,5R)-3-((6-Bromopyridin-2-yl)carbamoyl...)
Affinity DataIC50: 11nMAssay Description:Inhibition of complement factor D in human whole blood assessed as decrease in zymosan-induced AP activation mediated soluble MAC complex formation p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/30/2019
Entry Details Article
PubMedPDB3D3D Structure (crystal)
TargetCytochrome P450 2C9(Human)
Novartis Pharma

Curated by ChEMBL
LigandPNGBDBM171350(1-(2-((1R,3S,5R)-3-((6-Bromopyridin-2-yl)carbamoyl...)
Affinity DataIC50: 2.00E+4nMAssay Description:Inhibition of CYP2C9 (unknown origin) using diclofenac as substrateMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/30/2019
Entry Details Article
PubMed
TargetPotassium voltage-gated channel subfamily H member 2(Human)
Novartis Pharma

Curated by ChEMBL
LigandPNGBDBM171350(1-(2-((1R,3S,5R)-3-((6-Bromopyridin-2-yl)carbamoyl...)
Affinity DataIC50: 3.00E+4nMAssay Description:Inhibition of dofetilide binding to human ERGMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/30/2019
Entry Details Article
PubMed
TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM171350(1-(2-((1R,3S,5R)-3-((6-Bromopyridin-2-yl)carbamoyl...)
Affinity DataIC50: 11nMAssay Description:Inhibition of complement factor D in human whole blood assessed as decrease in zymosan-induced AP activation mediated soluble MAC complex formation p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/30/2019
Entry Details Article
PubMedPDB3D3D Structure (crystal)
TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM171350(1-(2-((1R,3S,5R)-3-((6-Bromopyridin-2-yl)carbamoyl...)
Affinity DataIC50: 6nMAssay Description:Inhibition of human complement factor D using Z-L-Lys-SBzl hydrochloride as substrate preincubated for 15 mins followed by substrate addition and mea...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
PubMedPDB3D3D Structure (crystal)